Navigation Links
John Theurer Cancer Center offers breakthrough radiation measurement technology
Date:5/17/2010

HACKENSACK, N.J. (May 17, 2010) John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS (Dose Verification System). John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

"Traditional radiation therapies rely on knowing the exact location of the tumor, but provide no guidance on quantifying the actual dose being delivered to the tumor," said Glen Gejerman, M.D., Co-Chief, Urologic Oncology and Director, Radiation Oncology, John Theurer Cancer Center. "With this implantable device, we can now offer critical same day radiation dose adjustments."

The DVS sensorsjust 2.1mm in diameter and 20mm longare implanted during a minimally invasive procedure and gather data on the precise amount of radiation being delivered to the tumor. Wireless technology transmits the information to a hand-held monitor and the amount of radiation absorbed is read at the end of each of the daily treatments, enabling doctors to verify that the patient is receiving the prescribed dose.

Deviations in dose delivered to the tumor, or radiation accidentally administered to normal tissue, can have a profound impact on long-term survival rates and quality of life for patients treated with radiation therapy. Accurate delivery of the appropriate dose of radiation is critical to tumor control and cure rate. A long-term clinical study of nearly 230 prostate cancer patients demonstrated statistical significance between dose and benefit, highlighting the importance of measuring the amount of dose delivered. 1

This is part of John Theurer Cancer Center's ongoing dedication to improving radiation oncology safety and precision through research and adopting the latest technological advancements. John Theurer Cancer Center is the most experienced cancer center in the tri-state area with this implantable device. Dr. Gejerman and his colleagues at John Theurer Cancer Center plan to continue studying the DVS technology to determine the optimal number of sensors to implant and the most favorable locations in the body to implant them. In doing so, they plan to streamline the process of radiation delivery and make it even more precise.

"John Theurer Cancer Center is committed to providing extraordinary care by offering patients innovative technologies to help us improve patient outcomes and to tackle the most complicated cases," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center. "We are excited to offer an unprecedented level of precision to physicians and added peace of mind to our prostate cancer patients."


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
2. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
3. Motorcycle Cancer Risk and ELF EMF Radiation Invasion of Gastrointestinal Melatonin
4. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
5. 5th Annual Brittiana 'Smile For Life' 5k run/walk - Helping Children Survive Cancer One Smile at a Time
6. Relax for Hope May 23 - a Spa Day Fundraiser for the American Cancer Soiety's Relay for Life in Lincoln City, Oregon.
7. CIGNA and Cancer Treatment Centers of America Reach New Agreement
8. Can Celebrex prevent cancer-causing colon polyps?
9. Study identifies 1 of the mechanisms behind breast cancer metastasis
10. NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link
11. New hope for better treatment for a rising cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: